Antengene Unveils Groundbreaking Preclinical Results of ATG-207 at ACR 2026 Annual Meeting #China #Shanghai #Antengene #Autoimmune_Diseases #ATG-207

Antengene Unveils Groundbreaking Preclinical Results of ATG-207 at ACR 2026 Annual Meeting #China #Shanghai #Antengene #Autoimmune_Diseases #ATG-207
Antengene Starts Pivotal Phase III Study of ATG-022 for Cancer Treatment #China #Shanghai #Antengene #ATG-022 #CLINCH-3
Antengene Unveils Breakthrough Findings on Combined Cancer Therapy Targeting CD73 and Selinexor #China #Shanghai #Antengene #Selinexor #ATG-037